Business Wire

MAXON

20.4.2022 18:10:09 CEST | Business Wire | Press release

Share
Maxon Adds Enhanced Functionality and Unprecedented Value to Maxon One

Maxon , the developers of professional software solutions for editors, filmmakers, motion designers and visual effects artists, today announced that all Maxon products are now included in its value-packed subscription: Cinema 4D, Redshift, Red Giant, Universe, Forger and now ZBrush, acquired in December of last year, are all included in Maxon One for the same affordable price. Additionally, Maxon unveiled its Spring 2022 product upgrades that include an incredible set of new features and enhancements. This multi-product, feature-rich update once again illustrates Maxon’s commitment to delivering consistent product development and superior value to the Maxon One offering.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220420005268/en/

“Our goal is to provide artists with trailblazing technology and workflows to create in all dimensions,” said David McGavran, Maxon CEO. “This expansive update across all of Maxon’s creative tools comes together to provide incredible value and opportunities for creative expression in Maxon One.”

See Maxon One in Action at NAB 2022 and on The 3D and Motion Design Show

Maxon will be hosting exclusive presentations from industry-leading artists in its Booth (#N5920) at NAB 2022, April 24-27, 2022. For those unable to attend the show, the presentations will be streaming simultaneously at 3DMotionShow.com .

Exciting new enhancements and upgrades to Maxon One products include:

Cinema 4D S26: Significant emphasis has been put on unifying workflows with the best technology from around the Maxon family – the additions of Redshift CPU and ZBrush’s automatic retopology tools. Cinema 4D Subscription Release 26 also includes great enhancements across the entire 3D workflow - Modeling, Animation, Simulation, Rendering.

Redshift: Redshift is Everywhere. With the initial release of Redshift CPU, users can make use of Redshift’s powerful materials and rendering on any system and a growing number of creative tools including Houdini, Maya, 3ds max, Blender, Katana, Vectorworks and Archicad. The new Redshift Standard material is easy to use and offers diverse shading models for improved photorealism.

Red Giant:

  • VFX Suite 3 introduces Real Lens Flares based on simulated optical models and ray traced light. This technology preview will evolve with the participation of our artistic community.
  • Magic Bullet Suite 16 adds new Halation and Optical Diffusion tools for Looks, along with OpenColorIO support.
  • Trapcode Suite 18 now offers M1 support for all Trapcode tools, and layer maps support in Particular.

Universe: Universe 6 adds exciting new tools providing many new options to be creative and enhance an artist’s workflow. Sketchify adds sketch- and toon-like effects to footage, ChromaTown creates chromatic streaks and blurs for warpy looks and transitions, Box Bokeh provides square or diamond shaped lens bokeh effects, and Stretch Transition adds a stretchy crossfade between clips for a warp-like transition. Combined with over 70 new presets, Universe 6 helps artists to get impressive results quickly in a fun and intuitive way.

Forger: The latest version of Forger reveals the first stage in Maxon’s plan to provide powerful hard-surface modeling capabilities to 3D artists. Built with Cinema 4D’s polygonal foundation, Forger now offers a selection of polygonal primitives: planes, cubes, spheres, cylinders, torus, pyramids, capsules, oil tanks, etc.

Maxon One subscribers can immediately download all product updates via Maxon App. Everyone can download a 14-day trial of the entire Maxon One offering from within Maxon App and experience for themselves all the great new features across the entire Maxon family of products.

More Details at maxon.net

About Maxon

Maxon makes powerful, yet approachable software solutions for content creators working in 2D and 3D design, motion graphics, visual effects and visualization. Maxon’s innovative product portfolio helps artists supercharge their creative workflows. Our product lines include the award-winning Cinema 4D suite of 3D modeling, simulation and animation technology; the creativity-on-the-go Forger mobile sculpting app; the diverse Red Giant lineup of revolutionary editing, motion design and filmmaking tools; the leading-edge, blazingly fast Redshift renderer; and ZBrush , the industry-standard digital sculpting and painting solution.

Maxon’s team is comprised of fun, passionate people who believe in building and empowering a successful artistic community. From our popular, inclusive events to our free Cineversity educational resources, Maxon recognizes that developing strong connections with creatives and fostering their professional growth is integral to our ability to stay on top of industry trends and better serve customers.

Maxon is part of the Nemetschek Group .

Link:

ClickThru

Social Media:

https://www.facebook.com/MaxonVFX

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release

REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release

In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release

- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release

Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye